IP Library Granted Patent US 12,109,035
Granted Patent B2
US 12,109,035 · App. 16/791,797 · Granted Oct 8, 2024

System and method for treating and monitoring post traumatic stress disorder (PTSD)

Inventors: Carolyn Mountford (East Ryde, AU); David Crompton (Highfields, AU); Nathan Tosh (Mount Lofty, AU); Rosanna Tremewan (Camp Hill, AU)
Assignee: DatChem
A61B5/4076A61B5/374A61N2/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,035
App. No.
16/791,797
Granted
Oct 8, 2024
Kind
B2
Abstract

A method and system for monitoring therapeutic interventions for treating a patient with PTSD comprises using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in the brain of the patient before treatment, treating the patient with at least one treatment protocol, after treatment, obtaining post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and comparing the results of the pre-treatment and post-treatment data to enable a determination of the effectiveness of the treatment.

Claims (26)

1. A method of monitoring therapeutic interventions for treating a patient with PTSD by:

using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in a brain of the patient before treatment, the at least one neuromarker chemical being at least one of Fuc 7, and PE-Histidine, using a comparator to compare the pre-treatment neural spectroscopic data with neural spectroscopic data of a healthy profile, treating the patient with at least one treatment protocol, after the at least one treatment protocol is performed on the patient, using the scanner to obtain post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and using the comparator to compare the pre-treatment and post-treatment neural spectroscopic data.

2. The method of claim 1 wherein the patient is treated with rTMS.

3. The method of claim 1 , wherein the patient is treated with a psychotherapy.

4. The method of claim 3 , wherein the psychotherapy is EMDR.

5. The method of claim 1 , wherein the patient is treated with a combination of at least two of rTMS, psychotherapies and pharmaceutical interventions.

6. The method of claim 1 , further including the step of obtaining mid-treatment neural spectroscopic data during the at least one treatment protocol, and comparing the mid-treatment data with the pre-treatment data.

7. The method of claim 1 , wherein the at least one treatment protocol continues, and obtaining post-treatment neural spectroscopic data is repeated to monitor the patient's post-treatment neural spectroscopic data.

8. The method of claim 1 , wherein the steps of obtaining neural spectroscopic data comprise obtaining the data using 2D COSY.

9. A system for monitoring therapeutic interventions for treating a patient with PTSD, comprising:

a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in a brain of the patient before any treatment protocol, and after at least one treatment protocol is performed on the patient, to obtain post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain, and a comparator for comparing the pre-treatment and post-treatment data to enable a determination of whether the treatment protocol was effective at improving PTSD, wherein the neuromarker chemical is at least one of Fuc 7, and PE-Histidine.

10. The system of claim 9 , wherein the treatment protocol is rTMS.

11. The system of claim 9 , wherein the treatment protocol is a psychotherapy.

12. The system of claim 11 , wherein the psychotherapy is EMDR.

13. The system of claim 9 , wherein the treatment protocol is a combination of at least two of rTMS, psychotherapies and pharmaceutical interventions.

14. The system of claim 9 , wherein the scanner obtains mid-treatment neural spectroscopic data during the at least one treatment protocol.

15. The system of claim 9 , wherein the scanner continues to obtain spectroscopic data to monitor a neurochemical profile of the patient to ensure no dysregulation of neurochemical markers are seen that could enable detection of the patient returning to an unhealthy state.

16. The system of claim 9 , wherein the scanner obtains pre-treatment and post-treatment neural spectroscopic data using 2D COSY.

17. A method of monitoring therapeutic interventions for treating a patient with PTSD by:

using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in a brain of the patient before at least one treatment protocol, the at least one neuromarker chemical being at least one of Fuc 7, and PE-Histidine, treating the patient with at least one treatment protocol; after at least one treatment protocol, using the scanner to obtain post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and using a comparator to compare the pre-treatment and post-treatment neural spectroscopic data to enable a determination of whether the treatment protocol was effective at treating PTSD.

18. A method of obtaining a pre-treatment condition of a patient for PTSD, comprising:

using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in a brain of the patient, the at least one neuromarker being at least one of Fuc 7, and PE-Histidine, and

using a comparator to compare the pre-treatment neural spectroscopic data with neural spectroscopic data of a healthy profile to determine a pre-treatment baseline condition of the patient.

19. A system for obtaining a pre-treatment condition of a patient for PTSD, comprising:

a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in a brain of the patient before treatment, the at least one neuromarker chemical being at least one of Fuc 7, and PE-Histidine; and

a comparator to compare the pre-treatment neural spectroscopic data with neural spectroscopic data of a healthy profile.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: TRANSLATIONAL RESEARCH INSTITUTE PTY LTD AS TRUSTEE FOR TRANSLATIONAL RESEARCH INSTITUTE TRUST
To: DATCHEM
Reel/Frame 057809/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2020
From: MOUNTFORD, CAROLYN; CROMPTON, DAVID; TREMEWAN, ROSANNA
To: TRANSLATIONAL RESEARCH INSTITUTE PTY LTD AS TRUSTEE FOR TRANSLATIONAL RESEARCH INSTITUTE TRUST
Reel/Frame 053647/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2020
From: TOSH, NATHAN
To: QUEENSLAND UNIVERSITY OF TECHNOLOGY
Reel/Frame 053647/0427 →
Continuity (2)
Provisional Application 62806400 · Feb 15, 2019
Related Publication 20200261012A1 · Aug 20, 2020